专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20170312315A1 Engineered Dendritic Cells and Uses for the Treatment of Cancer 审中-公开
公开(公告)号：US20170312315A1
公开(公告)日：2017-11-02
申请号：US15591468
申请日：2017-05-10
申请人： Intrexon Corporation , University of Pittsburgh-Of The Commonwealth System Of Higher Education
发明人： Mark BRAUGHLER , Prasanna Kumar , Walter J. Storkus , Hideho Okada
IPC分类号： A61K35/15 , A61K31/4245 , G01N33/68 , C07K14/54 , A61K31/00 , C12N5/0784 , A61K31/166 , A61K45/06 , A61K38/00
CPC分类号： A61K35/15 , A61K31/00 , A61K31/166 , A61K31/4245 , A61K38/00 , A61K45/06 , C07K14/5434 , C07K2319/715 , C12N5/0639 , C12N2501/23 , C12N2501/24 , C12N2510/00 , C12N2710/10343 , C12N2830/002 , C12N2840/203 , G01N33/6866 , G01N2333/57 , G01N2800/52 , A61K2300/00
摘要： This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.

2. 发明授权

US09273115B2 Method for controlling the biological activity of a protein in a vertebrate cell 有权
标题翻译：控制脊椎动物细胞中蛋白质生物活性的方法
公开(公告)号：US09273115B2
公开(公告)日：2016-03-01
申请号：US13145752
申请日：2010-01-22
申请人： Daniel Metzger , Pierre Chambon , Huimin Zhao , John Katzenellenbogen
发明人： Daniel Metzger , Pierre Chambon , Huimin Zhao , John Katzenellenbogen
IPC分类号： C12N15/00 , C07K14/72 , C12N9/90
CPC分类号： C07K14/721 , C07K2319/715 , C12N9/90
摘要： The present invention relates to a method for tightly temporally controlling the biological activity of a protein of interest in a vertebrate, upon induction of the activity of a fusion protein comprising said protein of interest and an ERM polypeptide containing a mutated ligand binding domain of the human oestrogen receptor α, with a synthetic ligand that does not interfere with oestrogen signalling. In particular, the present invention concerns a method for generating tightly temporally-controlled targeted somatic mutations in a vertebrate, preferably a mouse, by inducing the activity of a fusion protein comprising a site-specific recombinase protein and an ERM polypeptide, with a synthetic ligand devoid of oestrogenic and anti-oestrogenic activities.
摘要翻译：本发明涉及在诱导包含所述目的蛋白质的融合蛋白的活性和含有人的突变配体结合结构域的ERM多肽时紧密地暂时地控制脊椎动物中感兴趣的蛋白质的生物学活性的方法雌激素受体α与不影响雌激素信号传导的合成配体。特别地，本发明涉及通过用合成配体诱导包含位点特异性重组酶蛋白和ERM多肽的融合蛋白的活性，在脊椎动物，优选小鼠中产生紧密的时间控制的靶向体细胞突变的方法没有雌激素和抗雌激素活性。

3. 发明申请

US20140308247A1 Vectors Conditionally Expressing Protein 有权
标题翻译：有条件表达蛋白质的载体
公开(公告)号：US20140308247A1
公开(公告)日：2014-10-16
申请号：US14001943
申请日：2012-03-02
申请人： Jeremiah F. Roeth , Brandon Cuthbertson , Charles C. Reed , Sunil Chada , William E. Fogler , Fayas Khazi
发明人： Jeremiah F. Roeth , Brandon Cuthbertson , Charles C. Reed , Sunil Chada , William E. Fogler , Fayas Khazi
IPC分类号： A61K48/00 , C12N15/86
CPC分类号： A61K48/0025 , A61K38/1816 , A61K38/208 , A61K38/212 , A61K48/0066 , A61K48/0075 , C07K14/4713 , C07K14/505 , C07K14/5428 , C07K14/5434 , C07K14/56 , C07K14/565 , C07K14/70567 , C07K2319/70 , C07K2319/715 , C07K2319/81 , C12N15/85 , C12N15/86 , C12N2710/10343 , C12N2750/14143 , C12N2830/002 , C12N2830/75 , C12N2830/85 , C12N2840/203
摘要： This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing one or more proteins under the control of a gene expression modulation, system in the presence of activating ligand and uses for therapeutic purposes in animals. The vector may be provided to treat or prevent disease.
摘要翻译：本发明涉及治疗领域。最具体地，本发明提供了在活化配体存在下在基因表达调节系统的控制下有条件地表达一种或多种蛋白质的方法以及用于动物治疗目的的用途。可以提供载体来治疗或预防疾病。

4. 发明授权

US08236937B2 Methods and compositions for the detection and isolation of ligands 有权
标题翻译：用于检测和分离配体的方法和组合物
公开(公告)号：US08236937B2
公开(公告)日：2012-08-07
申请号：US12158383
申请日：2006-12-22
申请人： Henry M. Krause , Jens Tiefenbach
发明人： Henry M. Krause , Jens Tiefenbach
IPC分类号： A01K67/027
CPC分类号： A61K49/0008 , C07K2319/43 , C07K2319/715 , C07K2319/80 , C12Q1/6897 , G01N2500/02
摘要： A method for the detection and isolation of ligands, preferably nuclear receptor ligands, bound to their cognate receptors in live animals, is described. A novel composition comprising 1) a chimeric transcription factor containing a DNA-binding domain, preferably from a non-vertebrate transcription factor, fused to the ligand-binding domain (LBD) of a nuclear receptor, 2) a reporter system, driven by a promoter that contains binding sites for the chosen DNA-binding domain, 3) multiple affinity tags fused to the LBD fusion proteins to facilitate efficient purification, along with specifically associated molecules and 4) sequences required for simultaneous genomic integration of all three components above are described. To make use of the system, expression of the chimeric LBD protein is broadly induced.
摘要翻译：描述了用于检测和分离与活体动物中的其同源受体结合的配体，优选核受体配体的方法。一种新型组合物，其包含1）嵌合转录因子，其含有与核受体的配体结合结构域（LBD）融合的DNA结合结构域，优选来自非脊椎动物转录因子，2）报告系统，由描述了包含所选DNA结合结构域的结合位点的启动子，3）与LBD融合蛋白融合以促进有效纯化的多个亲和标签以及特异性相关分子以及4）上述所有三种组分的同时基因组整合所需的序列。为了利用该系统，广泛诱导了嵌合LBD蛋白的表达。

5. 发明申请

US20120164727A1 PRODUCTIVITY AUGMENTING PROTEIN FACTOR, NOVEL CELL LINES AND USES THEREOF 有权
标题翻译：生产力增强蛋白因子，新细胞系及其用途
公开(公告)号：US20120164727A1
公开(公告)日：2012-06-28
申请号：US12117475
申请日：2008-05-08
申请人： Volker Sandig , Ingo Jordan , Elisabeth Brundke
发明人： Volker Sandig , Ingo Jordan , Elisabeth Brundke
IPC分类号： C12N5/10 , C12N15/86 , C12N15/63 , C07K19/00 , C12N15/62 , C12N7/02 , C12N15/85
CPC分类号： C12N7/00 , C07K14/005 , C07K14/70567 , C07K2319/00 , C07K2319/09 , C07K2319/60 , C07K2319/715 , C12N2510/02 , C12N2710/10322 , C12N2710/16622 , C12N2710/16652
摘要： The present invention provides a method for preparing a non-adenoviral target virus or target proteins utilizing a potent expression cell line having stably integrated into its genome a gene encoding a specific heterologous regulator protein.
摘要翻译：本发明提供了使用在其基因组中稳定整合到编码特异性异源调节蛋白的基因的有效表达细胞系来制备非腺病毒靶病毒或靶蛋白的方法。

6. 发明申请

US20070192880A1 Horming response element binding transregulators 审中-公开
标题翻译： Horming响应元件结合式跨越器
公开(公告)号：US20070192880A1
公开(公告)日：2007-08-16
申请号：US10574322
申请日：2004-10-04
申请人： Mesut Muyan , Jing Huang
发明人： Mesut Muyan , Jing Huang
IPC分类号： A01K67/027 , A61K48/00 , C07H21/04 , C12P21/06 , C07K14/82
CPC分类号： C12N15/62 , C07K14/4702 , C07K2319/715 , C12N2799/022 , C12N2830/008
摘要： Disclosed are compositions and methods for ERE-binding tansregulators that specifically and potently regulate ERE-containing genes. To accomplish this, we took advantage of the modular nature of ER and initially designed a monomeric ERE binding module by co-joining two DNA binding domains with the hinge domain. Integradon of strong activation or repressor domains from other transcription factors into this module generated constitutively active ERE-binding activators (EBAs) and ERE-binding repressors (EBRs) respectively. These novel transregulators are the basis for the targeted regulation of ERE containing genes, the identification of estrogen reponsive gene networks, and the development of alternative/complementary therapeutic approaches for estrogen target tissue cancers.
摘要翻译：公开了特异性和有效调节含ERE的基因的ERE结合的调节物的组合物和方法。为了实现这一点，我们利用了ER的模块化特性，并最初通过将两个DNA结合结构域与铰链域共同连接来设计单体ERE结合模块。来自其他转录因子的强激活或抑制子结构域的整合体分别产生组成型活性ERE结合激活因子（EBAs）和ERE结合阻遏物（EBRs）。这些新型跨越调控因子是靶向调控含ERE基因，雌激素反应基因网络的鉴定以及雌激素靶组织癌的替代/补充治疗方法的发展的基础。

7. 发明申请

US20060258840A1 Peroxisome proliferator-activated receptor 审中-公开
标题翻译：过氧化物酶体增殖物激活受体
公开(公告)号：US20060258840A1
公开(公告)日：2006-11-16
申请号：US10541892
申请日：2004-01-16
申请人： Ralph Mosley , Brian McKeever , Joel Berger
发明人： Ralph Mosley , Brian McKeever , Joel Berger
IPC分类号： C07K14/705 , G01N33/567 , C07H21/04 , C12P21/06
CPC分类号： G01N33/6872 , C07K14/70567 , C07K2319/715 , C07K2319/80 , G01N33/6875
摘要： The present invention features mutated forms of PPAR ligand binding domain polypeptides that: (1) bind a partial PPAR agonist; and (2) is bound or activated by a full PPAR agonist to a lesser extent than the wild-type receptor. The mutated ligand binding domain contains an amino acid sequence wherein one or more interactions that preferentially (preferably solely) occurs between a full PPAR agonist and the AF-2 domain of a wild-type PPAR are modified. Preferably, the mutated ligand binding domain is selectively bound or activated by a partial PPAR agonist.
摘要翻译：本发明涉及PPAR配体结合结构域多肽的突变形式：（1）结合部分PPAR激动剂; 和（2）由完全PPAR激动剂结合或活化的程度低于野生型受体。突变的配体结合结构域含有氨基酸序列，其中在完全PPAR激动剂和野生型PPAR的AF-2结构域之间优先（优选单独地）发生的一个或多个相互作用被修饰。优选地，突变的配体结合结构域由部分PPAR激动剂选择性结合或活化。

8. 发明授权

US07112715B2 Transgenic mouse for targeted recombination mediated by modified Cre-ER 有权
标题翻译：用于通过改良Cre-ER介导的靶向重组的转基因小鼠
公开(公告)号：US07112715B2
公开(公告)日：2006-09-26
申请号：US09853033
申请日：2001-05-11
申请人： Pierre Chambon , Daniel Metzger
发明人： Pierre Chambon , Daniel Metzger
IPC分类号： G01N33/00
CPC分类号： C12N15/8509 , A01K67/0276 , A01K2217/05 , A01K2217/075 , A01K2217/20 , A01K2217/203 , A01K2227/105 , A01K2267/03 , A01K2267/0331 , A01K2267/0362 , C07K14/4702 , C07K14/4741 , C07K14/70567 , C07K14/721 , C07K14/8125 , C07K2319/00 , C07K2319/715 , C12N9/00 , C12N15/63 , C12N15/85 , C12N2800/30 , C12N2830/008 , C12N2830/85
摘要： The present invention relates to a metazoan organism, with the exception of humans, and in particular a mouse, characterized in that at least one cell of this organism comprises at least one fusion protein between a recombinase Cre and a modified ligand binding domain of the nuclear estrogen receptor alpha, allowing the inactive fused recombinase to be induced by synthetic antiestrogens, but not by natural estrogens, and one or more DNA sequences of interest belonging to the genome of said organism into which one or more sites of recognition of said recombinase protein are inserted. The invention also covers the methods using said organism for the screening of medicaments, the mutagenesis and the analysis of the biological function of the DNA sequences) of interest, in particular of gene(s) of interest, such as RXRα.
摘要翻译：本发明涉及除人之外的后生动物生物，特别是小鼠，其特征在于，该生物体的至少一个细胞包含重组酶Cre与核的修饰的配体结合结构域之间的至少一个融合蛋白雌激素受体α，允许无效融合重组酶由合成抗雌激素诱导，但不由天然雌激素诱导，以及一个或多个感兴趣的属于所述生物体基因组的感兴趣的DNA序列，其中所述重组酶蛋白的一个或多个识别位点是插入。本发明还涵盖使用所述生物体筛选药物的方法，感兴趣的DNA序列的生物学功能的诱变和分析，特别是感兴趣的基因，例如RXRα， / SUB>。

9. 发明申请

US20040171800A9 Gamma retinoic acid receptor 失效
标题翻译： γ视黄酸受体
公开(公告)号：US20040171800A9
公开(公告)日：2004-09-02
申请号：US09797727
申请日：2001-03-01
申请人： THE SALK INSTITUTE FOR BIOLOGICAL STUDIES , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： Fumimaro Takaku , Takashi Ishikawa , Michio Imawari , Ronald Mark Evans , Kazuhiko Umesono
IPC分类号： C12Q001/68 , C07H021/02 , C07H021/04 , C07K005/00 , C07K007/00 , C07K016/00 , C07K017/00 , A61K038/00 , C07K001/00 , C07K014/00
CPC分类号： C07K14/72 , A61K38/00 , C07K14/70567 , C07K14/721 , C07K2319/00 , C07K2319/715 , C07K2319/80 , Y10S530/826 , Y10S530/846
摘要： A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRARnull, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.
摘要翻译：公开了一种新型的视黄酸受体。新型受体由携带在质粒pGEM-hRARgamma上的cDNA编码，其已经保藏在美国典型培养物保藏中心用于专利。还公开了嵌合受体蛋白。嵌合体含有来自新的视黄酸受体的至少一个功能结构域。

10. 发明授权

US06635429B1 Heterodimeric nuclear receptors proteins, genes encoding same, and usage thereof 失效
标题翻译：异二聚体核受体蛋白，编码相同的基因及其用途
公开(公告)号：US06635429B1
公开(公告)日：2003-10-21
申请号：US08216592
申请日：1994-03-23
申请人： Mark Leid , Philippe Kastner , Pierre Chambon
发明人： Mark Leid , Philippe Kastner , Pierre Chambon
IPC分类号： G01N3353
CPC分类号： C07K14/70567 , C07K2319/715 , C07K2319/80
摘要： The present invention is based in part on the novel observation that two different types of nuclear receptors, retinoic acid receptors (RAR) and thyroid receptors (TR) dimerize with a RX receptor (RXR) to form a heterodimer which is capable of binding to retinoic acid response elements (RARE) or thyroid receptor response elements (TRE) at physiological conditions. In addition, the present invention discloses that RXR homodimers are capable of binding to RARE's. Based on this observation, the present invention provides novel dimeric proteins, methods of identifying agents capable of binding the dimers of the present invention, methods of identifying DNA sequences capable of being bound by the dimers and methods to identify RA metabolic enzymes and proteins which are required for the activation function of nuclear receptors.
摘要翻译：本发明部分基于两种不同类型的核受体，视黄酸受体（RAR）和甲状腺受体（TR）与RX受体（RXR）二聚化以形成能够结合视黄酸的异源二聚体的新观察酸反应元素（RARE）或甲状腺受体反应元件（TRE）。另外，本发明公开了RXR同型二聚体能够与RARE结合。基于该观察，本发明提供了新颖的二聚蛋白，鉴定能够结合本发明的二聚体的试剂的方法，鉴定能够被二聚体结合的DNA序列的方法以及鉴定RA代谢酶和蛋白质的方法核受体激活功能所需。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式